

Assessment of Dasatinib versus Nilotinib as Upfront Therapy for Chronic-Phase of Chronic Myeloid Leukemia in Qatar: A Cost Effectiveness Analysis

Highlights:

What do we already know about this topic?

The goals for standard treatment for CML-CP using TKIs such as nilotinib, dasatinib has well been established to achieve clinical remission while optimizing patient's quality of life.

How does your research contribute to the Cancer Control field?

Upfront therapy of chronic myeloid leukemia –chronic phase patients by nilotinib plan appears to be more cost-effective than dasatinib i.e. more cost-effective strategy in terms of incremental costs per additional MMR/CCyR response gained.

What are your research's implications towards theory, practice, or policy?

The main finding identified will provide clinicians and healthcare policy makers in Qatar with better CML treatment decision making.